Table 1.

Demographic, clinical, and laboratory characteristics of women with behaviorally (BAH) and perinatally acquired HIV (PAH).

	Behaviorally acquired HIV (BAH) N = 27 subjects (n = 33 pregnancies)	Perinatally acquired HIV (PAH) N = 11 subjects (n = 15 pregnancies)
Race
Hispanics	6	7 (0.47%)
African Americans	21 (78%)	4
Highly active antiretroviral therapy (HAART)	n = 33	n = 15
Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)	31	15
NNRTI	8	1
PI	23	13
HIV RNA levels (copies/ml at delivery)	n = 33	n = 15
<400	29 (88%)	9 (60%)
400–1000	1	1
1000–< 10,000	1	2
> 10,000	2	3 (20%)
Birth weight (g)	n = 31	n = 15
1500–2000	2	1
2000–2500	2	1
2500–3000	4	12 (80%)
> 3000	23 (66%)	2
Gestational age (weeks)	n = 31	n = 15
39–40	20 (65%)	1
37–38	9 (29%)	12 (80%)
< 37	2	2
Mode of delivery	n = 33	n = 15
Cesarean section	13 (39%)	12 (80%)
Normal spontaneous vaginal delivery (NSVD)	20	3